Ten years of human metapneumovirus research

Journal of Clinical Virology

Volumn 53, Issue 2, 2012, Pages 97-105

  Feuillet, F ^a,b   Lina, B ^a   Rosa Calatrava, M ^a   Boivin, G ^a,b  

^a UNIVERSITÉ LYON 1   (France)

^b LAVAL UNIVERSITY   (Canada)

Author keywords

Fusion glycoprotein; HMPV; HRSV; Paramyxoviridae; Therapeutic; Vaccine

Indexed keywords

DNA VACCINE; INACTIVATED VIRUS VACCINE; LIVE VACCINE; MONOCLONAL ANTIBODY; PALIVIZUMAB; RIBAVIRIN; SINGLE STRANDED RNA; SMALL INTERFERING RNA; SUBUNIT VACCINE;

ANTIVIRAL THERAPY; DRUG MECHANISM; HUMAN; HUMAN METAPNEUMOVIRUS; HUMAN METAPNEUMOVIRUS INFECTION; LIFE CYCLE; MEDICAL RESEARCH; NONHUMAN; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVIEW; VIRUS ATTACHMENT; VIRUS MORPHOLOGY; VIRUS REPLICATION;

ADULT; ANIMALS; ANTIVIRAL AGENTS; BIOMEDICAL RESEARCH; BRONCHIOLITIS, VIRAL; CELL LINE; CHILD; CHILD, PRESCHOOL; HUMANS; METAPNEUMOVIRUS; MICE; PARAMYXOVIRIDAE INFECTIONS; PNEUMONIA, VIRAL; VIRAL VACCINES;

EID: 84855539522     PISSN: 13866532     EISSN: 18735967     Source Type: Journal    
DOI: 10.1016/j.jcv.2011.10.002     Document Type: Review

References (77)

1. van den Hoogen B.G., de Jong J.C., Groen J., Kuiken T., de Groot R., Fouchier R.A., et al. A newly discovered human pneumovirus isolated from young children with respiratory tract disease. Nat Med 2001, 7:719-724.
2. van den Hoogen B.G., Herfst S., Sprong L., Cane P.A., Forleo-Neto E., de Swart R.L., et al. Antigenic and genetic variability of human metapneumoviruses. Emerg Infect Dis 2004, 10:658-666.
3. Huck B., Egger M., Bertz H., Peyerl-Hoffman G., Kern W.V., Neumann-Haefelin D., et al. Human metapneumovirus infection in a hematopoietic stem cell transplant recipient with relapsed multiple myeloma and rapidly progressing lung cancer. J Clin Microbiol 2006, 44:2300-2303.
4. Skiadopoulos M.H., Biacchesi S., Buchholz U.J., Riggs J.M., Surman S.R., Amaro-Carambot E., et al. The two major human metapneumovirus genetic lineages are highly related antigenically, and the fusion (F) protein is a major contributor to this antigenic relatedness. J Virol 2004, 78:6927-6937.
5. van den Hoogen B.G., Bestebroer T.M., Osterhaus A.D., Fouchier R.A. Analysis of the genomic sequence of a human metapneumovirus. Virology 2002, 295:119-132.
6. Freymuth F., Vabret A., Lebon P., Legrand L., Bach N., Brouard J., et al. Le Métapneumovirus humain. Virologie 2004, 8:413-423.
7. Kahn J.S. Epidemiology of human metapneumovirus. Clin Microbiol Rev 2006, 19:546-557.
8. Palacios G., Lowenstine L.J., Cranfield M.R., Gilardi K.V., Spelman L., Lukasik-Braum M., et al. Human metapneumovirus infection in wild mountain gorillas, Rwanda. Emerg Infect Dis 2011, 17:711-713.
9. Louie J.K., Schnurr D.P., Pan C.Y., Kiang D., Carter C., Tougaw S., et al. A summer outbreak of human metapneumovirus infection in a long-term-care facility. J Infect Dis 2007, 196:705-708.
10. Papenburg J., Boivin G. The distinguishing features of human metapneumovirus and respiratory syncytial virus. Rev Med Virol 2010, 20:245-260.
11. Boivin G., De Serres G., Hamelin M.E., Cote S., Argouin M., Tremblay G., et al. An outbreak of severe respiratory tract infection due to human metapneumovirus in a long-term care facility. Clin Infect Dis 2007, 44:1152-1158.
12. Darniot M., Pitoiset C., Petrella T., Aho S., Pothier P., Manoha C. Age-associated aggravation of clinical disease after primary metapneumovirus infection of BALB/c mice. J Virol 2009, 83:3323-3332.
13. de Graaf M. Metapneumovirus: determinants of host range and replication. Doctoral thesis; 2009. http://repub.eur.nl/res/pub/16401.
14. Tollefson S.J., Cox R.G., Williams J.V. Studies of culture conditions and environmental stability of human metapneumovirus. Virus Res 2010, 151:54-59.
15. Reina J., Ferres F., Alcoceba E., Mena A., de Gopegui E.R., Figuerola J. Comparison of different cell lines and incubation times in the isolation by the shell vial culture of human metapneumovirus from pediatric respiratory samples. J Clin Virol 2007, 40:46-49.
16. Schildgen V., Lusebrink J., Ditt V., Tillmann R., Simon A., Muller A., et al. Human HepG2 cells support respiratory syncytial virus and human metapneumovirus replication. J Virol Methods 2010, 163:74-81.
17. Boivin G., Abed Y., Pelletier G., Ruel L., Moisan D., Cote S., et al. Virological features and clinical manifestations associated with human metapneumovirus: a new paramyxovirus responsible for acute respiratory-tract infections in all age groups. J Infect Dis 2002, 186:1330-1334.
18. Kukavica-Ibrulj I., Boivin G. Detection of human metapneumovirus antigens in nasopharyngeal aspirates using an enzyme immunoassay. J Clin Virol 2009, 44:88-90.
19. Jun K.R., Woo Y.D., Sung H., Kim M.N. Detection of human metapneumovirus by direct antigen test and shell vial cultures using immunofluorescent antibody staining. J Virol Methods 2008, 152:109-111.
20. Maertzdorf J., Wang C.K., Brown J.B., Quinto J.D., Chu M., de Graaf M., et al. Real-time reverse transcriptase PCR assay for detection of human metapneumoviruses from all known genetic lineages. J Clin Microbiol 2004, 42:981-986.
21. Gharabaghi F., Hawan A., Drews S.J., Richardson S.E. Evaluation of multiple commercial molecular and conventional diagnostic assays for the detection of respiratory viruses in children. Clin Microbiol Infect 2011, Article first published online: 24 june 2011, Early View.
22. Terrier O.C.G., Lina B. La génétique inverse chez les paramyxovirus: applications et perspectives. Virologie 2008, 12:15-25.
23. Thammawat S., Sadlon T.A., Hallsworth P.G., Gordon D.L. Role of cellular glycosaminoglycans and charged regions of viral G protein in human metapneumovirus infection. J Virol 2008, 82:11767-11774.
24. Cseke G., Maginnis M.S., Cox R.G., Tollefson S.J., Podsiad A.B., Wright D.W., et al. Integrin alphavbeta1 promotes infection by human metapneumovirus. Proc Natl Acad Sci USA 2009, 106:1566-1571.
25. Smith E.C., Popa A., Chang A., Masante C., Dutch R.E. Viral entry mechanisms: the increasing diversity of paramyxovirus entry. FEBS J 2009, 276:7217-7227.
26. White J.M., Delos S.E., Brecher M., Schornberg K. Structures and mechanisms of viral membrane fusion proteins: multiple variations on a common theme. Crit Rev Biochem Mol Biol 2008, 43:189-219.
27. Hernandez L.D., Hoffman L.R., Wolfsberg T.G., White J.M. Virus-cell and cell-cell fusion. Ann Rev Cell Dev Biol 1996, 12:627-661.
28. Kielian M., Rey F.A. Virus membrane-fusion proteins: more than one way to make a hairpin. Nat Rev Microbiol 2006, 4:67-76.
29. Brändén C.-I., Tooze J. Introduction to protein structure 1999, Garland Pub, New York. 2nd ed.
30. Gardner A.E., Dutch R.E. A conserved region in the F(2) subunit of paramyxovirus fusion proteins is involved in fusion regulation. J Virol 2007, 81:8303-8314.
31. Cseke G., Wright D.W., Tollefson S.J., Johnson J.E., Crowe J.E., Williams J.V. Human metapneumovirus fusion protein vaccines that are immunogenic and protective in cotton rats. J Virol 2007, 81:698-707.
32. Gardner A.E., Martin K.L., Dutch R.E. A conserved region between the heptad repeats of paramyxovirus fusion proteins is critical for proper F protein folding. Biochemistry 2007, 46:5094-5105.
33. Schowalter R.M., Chang A., Robach J.G., Buchholz U.J., Dutch R.E. Low-pH triggering of human metapneumovirus fusion: essential residues and importance in entry. J Virol 2009, 83:1511-1522.
34. Herfst S., Mas V., Ver L.S., Wierda R.J., Osterhaus A.D., Fouchier R.A., et al. Low-pH-induced membrane fusion mediated by human metapneumovirus F protein is a rare, strain-dependent phenomenon. J Virol 2008, 82:8891-8895.
35. Easton A.J., Domachowske J.B., Rosenberg H.F. Animal pneumoviruses: molecular genetics and pathogenesis. Clin Microbiol Rev 2004, 17:390-412.
36. Mackay I.M., Jacob K.C., Woolhouse D., Waller K., Syrmis M.W., Whiley D.M., et al. Molecular assays for detection of human metapneumovirus. J Clin Microbiol 2003, 41:100-105.
37. Vargas S.O., Kozakewich H.P., Perez-Atayde A.R., McAdam A.J. Pathology of human metapneumovirus infection: insights into the pathogenesis of a newly identified respiratory virus. Pediatr Dev Pathol 2004, 7:478-486.
38. Wyde P.R., Chetty S.N., Jewell A.M., Boivin G., Piedra P.A. Comparison of the inhibition of human metapneumovirus and respiratory syncytial virus by ribavirin and immune serum globulin in vitro. Antiviral Res 2003, 60:51-59.
39. Hamelin M.E., Prince G.A., Boivin G. Effect of ribavirin and glucocorticoid treatment in a mouse model of human metapneumovirus infection. Antimicrob Agents Chemother 2006, 50:774-777.
40. Graci J.D., Cameron C.E. Mechanisms of action of ribavirin against distinct viruses. Rev Med Virol 2006, 16:37-48.
41. Bonney D., Razali H., Turner A., Will A. Successful treatment of human metapneumovirus pneumonia using combination therapy with intravenous ribavirin and immune globulin. Br J Haematol 2009, 145:667-669.
42. Group T.I.-R.S. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998, 102:531-537.
43. Ulbrandt N.D., Ji H., Patel N.K., Riggs J.M., Brewah Y.A., Ready S., et al. Isolation and characterization of monoclonal antibodies which neutralize human metapneumovirus in vitro and in vivo. J Virol 2006, 80:7799-7806.
44. Hamelin M.E., Couture C., Sackett M., Kiener P., Suzich J., Ulbrandt N., et al. The prophylactic administration of a monoclonal antibody against human metapneumovirus attenuates viral disease and airways hyperresponsiveness in mice. Antivir Ther 2008, 13:39-46.
45. Hamelin M.E., Gagnon C., Prince G.A., Kiener P., Suzich J., Ulbrandt N., et al. Prophylactic and therapeutic benefits of a monoclonal antibody against the fusion protein of human metapneumovirus in a mouse model. Antiviral Res 2010, 88:31-37.
46. Williams I.G. Enfuvirtide (Fuzeon): the first fusion inhibitor. Int J Clin Pract 2003, 57:890-897.
47. Cianci C., Meanwell N., Krystal M. Antiviral activity and molecular mechanism of an orally active respiratory syncytial virus fusion inhibitor. J Antimicrob Chemother 2005, 55:289-292.
48. Deffrasnes C., Hamelin M.E., Prince G.A., Boivin G. Identification and evaluation of a highly effective fusion inhibitor for human metapneumovirus. Antimicrob Agents Chemother 2008, 52:279-287.
49. Grassmann R., Jeang K.T. The roles of microRNAs in mammalian virus infection. Biochim Biophys Acta 2008, 1779:706-711.
50. DeVincenzo J., Cehelsky J.E., Alvarez R., Elbashir S., Harborth J., Toudjarska I., et al. Evaluation of the safety, tolerability and pharmacokinetics of ALN-RSV01, a novel RNAi antiviral therapeutic directed against respiratory syncytial virus (RSV). Antiviral Res 2008, 77:225-231.
51. Alvarez R., Elbashir S., Borland T., Toudjarska I., Hadwiger P., John M., et al. RNA interference-mediated silencing of the respiratory syncytial virus nucleocapsid defines a potent antiviral strategy. Antimicrob Agents Chemother 2009, 53:3952-3962.
52. Deffrasnes C., Cavanagh M.H., Goyette N., Cui K., Ge Q., Seth S., et al. Inhibition of human metapneumovirus replication by small interfering RNA. Antivir Ther 2008, 13:821-832.
53. Kapikian A.Z., Mitchell R.H., Chanock R.M., Shvedoff R.A., Stewart C.E. An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine. Am J Epidemiol 1969, 89:405-421.
54. Kim H.W., Canchola J.G., Brandt C.D., Pyles G., Chanock R.M., Jensen K., et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol 1969, 89:422-434.
55. Ottolini M.G., Porter D.D., Hemming V.G., Prince G.A. Enhanced pulmonary pathology in cotton rats upon challenge after immunization with inactivated parainfluenza virus 3 vaccines. Viral Immunol 2000, 13:231-236.
56. De Swart R.L., Kuiken T., Timmerman H.H., van Amerongen G., Van Den Hoogen B.G., Vos H.W., et al. Immunization of macaques with formalin-inactivated respiratory syncytial virus (RSV) induces interleukin-13-associated hypersensitivity to subsequent RSV infection. J Virol 2002, 76:11561-11569.
57. Hamelin M.E., Couture C., Sackett M.K., Boivin G. Enhanced lung disease and Th2 response following human metapneumovirus infection in mice immunized with the inactivated virus. J Gen Virol 2007, 88:3391-3400.
58. de Swart R.L., van den Hoogen B.G., Kuiken T., Herfst S., van Amerongen G., Yuksel S., et al. Immunization of macaques with formalin-inactivated human metapneumovirus induces hypersensitivity to hMPV infection. Vaccine 2007, 25:8518-8528.
59. Biacchesi S., Skiadopoulos M.H., Tran K.C., Murphy B.R., Collins P.L., Buchholz U.J. Recovery of human metapneumovirus from cDNA: optimization of growth in vitro and expression of additional genes. Virology 2004, 321:247-259.
60. Buchholz U.J., Nagashima K., Murphy B.R., Collins P.L. Live vaccines for human metapneumovirus designed by reverse genetics. Expert Rev Vaccines 2006, 5:695-706.
61. Biacchesi S., Skiadopoulos M.H., Yang L., Lamirande E.W., Tran K.C., Murphy B.R., et al. Recombinant human Metapneumovirus lacking the small hydrophobic SH and/or attachment G glycoprotein: deletion of G yields a promising vaccine candidate. J Virol 2004, 78:12877-12887.
62. Buchholz U.J., Biacchesi S., Pham Q.N., Tran K.C., Yang L., Luongo C.L., et al. Deletion of M2 gene open reading frames 1 and 2 of human metapneumovirus: effects on RNA synthesis, attenuation, and immunogenicity. J Virol 2005, 79:6588-6597.
63. Tang R.S., Schickli J.H., MacPhail M., Fernandes F., Bicha L., Spaete J., et al. Effects of human metapneumovirus and respiratory syncytial virus antigen insertion in two 3' proximal genome positions of bovine/human parainfluenza virus type 3 on virus replication and immunogenicity. J Virol 2003, 77:10819-10828.
64. Tang R.S., Mahmood K., Macphail M., Guzzetta J.M., Haller A.A., Liu H., et al. A host-range restricted parainfluenza virus type 3 (PIV3) expressing the human metapneumovirus (hMPV) fusion protein elicits protective immunity in African green monkeys. Vaccine 2005, 23:1657-1667.
65. Pham Q.N., Biacchesi S., Skiadopoulos M.H., Murphy B.R., Collins P.L., Buchholz U.J. Chimeric recombinant human metapneumoviruses with the nucleoprotein or phosphoprotein open reading frame replaced by that of avian metapneumovirus exhibit improved growth in vitro and attenuation in vivo. J Virol 2005, 79:15114-15122.
66. Skiadopoulos M.H., Biacchesi S., Buchholz U.J., Amaro-Carambot E., Surman S.R., Collins P.L., et al. Individual contributions of the human metapneumovirus F, G, and SH surface glycoproteins to the induction of neutralizing antibodies and protective immunity. Virology 2006, 345:492-501.
67. Herfst S., de Graaf M., Schrauwen E.J., Ulbrandt N.D., Barnes A.S., Senthil K., et al. Immunization of Syrian golden hamsters with F subunit vaccine of human metapneumovirus induces protection against challenge with homologous or heterologous strains. J Gen Virol 2007, 88:2702-2709.
68. Herfst S., Schrauwen E.J., de Graaf M., van Amerongen G., van den Hoogen B.G., de Swart R.L., et al. Immunogenicity and efficacy of two candidate human metapneumovirus vaccines in cynomolgus macaques. Vaccine 2008, 26:4224-4230.
69. Bembridge G.P., Rodriguez N., Garcia-Beato R., Nicolson C., Melero J.A., Taylor G. DNA encoding the attachment (G) or fusion (F) protein of respiratory syncytial virus induces protection in the absence of pulmonary inflammation. J Gen Virol 2000, 81:2519-2523.
70. Vuola J.M., Keating S., Webster D.P., Berthoud T., Dunachie S., Gilbert S.C., et al. Differential immunogenicity of various heterologous prime-boost vaccine regimens using DNA and viral vectors in healthy volunteers. J Immunol 2005, 174:449-455.
71. Safdar A. Immune modulatory activity of ribavirin for serious human metapneumovirus disease: early i.v. therapy may improve outcomes in immunosuppressed SCT recipients. Bone Marrow Transplant 2008, 41:707-708.
72. Raza K., Ismailjee S.B., Crespo M., Studer S.M., Sanghavi S., Paterson D.L., et al. Successful outcome of human metapneumovirus (hMPV) pneumonia in a lung transplant recipient treated with intravenous ribavirin. J Heart Lung Transplant 2007, 26:862-864.
73. Kamble R.T., Bollard C., Demmler G., LaSala P.R., Carrum G. Human metapneumovirus infection in a hematopoietic transplant recipient. Bone Marrow Transplant 2007, 40:699-700.
74. Wyde P.R., Moylett E.H., Chetty S.N., Jewell A., Bowlin T.L., Piedra P.A. Comparison of the inhibition of human metapneumovirus and respiratory syncytial virus by NMSO3 in tissue culture assays. Antiviral Res 2004, 63:51-59.
75. Krusat T., Streckert H.J. Heparin-dependent attachment of respiratory syncytial virus (RSV) to host cells. Arch Virol 1997, 142:1247-1254.
76. Yim K.C., Cragin R.P., Boukhvalova M.S., Blanco J.C., Hamlin M.E., Boivin G., et al. Human metapneumovirus: enhanced pulmonary disease in cotton rats immunized with formalin-inactivated virus vaccine and challenged. Vaccine 2007, 25:5034-5040.
77. Biacchesi S., Pham Q.N., Skiadopoulos M.H., Murphy B.R., Collins P.L., Buchholz U.J. Infection of nonhuman primates with recombinant human metapneumovirus lacking the SH, G, or M2-2 protein categorizes each as a nonessential accessory protein and identifies vaccine candidates. J Virol 2005, 79:12608-12613.